HilleVax

Hille Vax

Biotechnology, 75 State St, Boston, Massachusetts, 02109, United States, 51-200 Employees

hillevax.com

  • twitter
  • LinkedIn

phone no Phone Number: 88********

Who is HILLEVAX

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine cand...

Read More

map
  • 75 State St, Boston, Massachusetts, 02109, United States Headquarters: 75 State St, Boston, Massachusetts, 02109, United States
  • 2021 Date Founded: 2021
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from HILLEVAX

HilleVax Org Chart and Mapping

Employees

Lynn Ferrucci

Vice President Human Resources

Robbie Gay

Director, Quality Systems & Compliance

Lauren Hughes

Quality Systems Manager

Marlon Velasco

Sr. Director, Information Technology

Lynne Martin

Director, Quality Assurance Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding HilleVax

Answer: HilleVax's headquarters are located at 75 State St, Boston, Massachusetts, 02109, United States

Answer: HilleVax's phone number is 88********

Answer: HilleVax's official website is https://hillevax.com

Answer: HilleVax's revenue is $50 Million to $100 Million

Answer: HilleVax's SIC: 2836

Answer: HilleVax's NAICS: 325414

Answer: HilleVax has 51-200 employees

Answer: HilleVax is in Biotechnology

Answer: HilleVax contact info: Phone number: 88******** Website: https://hillevax.com

Answer: HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access